Phase I clinical studies with WR-2721
Toxicity studies of S-2-(3 aminopropylamino)-ethylphosphorothioic acid (WR-2721) access patients in remission following radiation therapy. The dose has been escalated from 25 to 250 mg/m2 without significant symptoms. Inconsistent variation in the systolic blood pressure in some patients has been observed over an 8-10-point range without producing any symptoms. Combining WR-2721 with conventional radiotherapy is contemplated by intravenous injection the drug 20 to 30 minutes before irradiation. This will start as weekly injections, and the number of weekly injections will be increased progessively. Animal studies suggest that the level already safely reached could give significant protection to the normal tissues without protecting tumor.
- OSTI ID:
- 6008502
- Journal Information:
- Cancer Clin. Trials; (United States), Journal Name: Cancer Clin. Trials; (United States) Vol. 3:3; ISSN CCTRD
- Country of Publication:
- United States
- Language:
- English
Similar Records
Interspecies comparison of the tissue distribution of WR-2721, a radioprotective drug
Protective effects of WR-2721 against radiation-induced injury of murine gut, testis, lung, and lung tumor nodules
Related Subjects
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKYLATING AGENTS
BLOOD PRESSURE
DOSE-RESPONSE RELATIONSHIPS
DRUGS
INJECTION
INTAKE
INTRAVENOUS INJECTION
MEDICINE
NUCLEAR MEDICINE
PATIENTS
RADIOLOGY
RADIOPROTECTIVE SUBSTANCES
RADIOTHERAPY
THERAPY
TOXICITY